Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 Dichloride and Paclitaxel in Bone Metastatic Breast Cancer
NCT04090398Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2020
- Primary completion
- Jun 2027
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in breast cancer, sponsored by National Cancer Institute. Started Aug 2020; status: active, not recruiting.
02
Drugs
radium-223 dichloride
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04090398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04090398.